UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 13,
2020
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
209 Perry Parkway, Suite 13
Gaithersburg, MD
|
|
20877
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (301)
825-5320
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001
|
CBMG
|
The Nasdaq Global Select Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD
Disclosure.
Attached
as Exhibit 99.1 to this Current Report is the form of presentation
that Cellular Biomedicine Group, Inc. (the “Company”)
intends to use in connection with a virtual R&D Showcase to be
held at 8:00 AM Eastern Standard Time on Monday, July 13, 2020.
Attached as Exhibit 99.2 to this Current Report is the Press
Release for the presentation.
The
foregoing (including Exhibit 99.1 and Exhibit 99.2) is being
furnished pursuant to Item 7.01 and will not be deemed to be filed
for purposes of Section 18 of the Securities and Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise be
subject to the liabilities of that section, nor will it be deemed
to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Presentation, dated
July 13, 2020
Press
Release, dated July 13, 2020
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
Date:
July 13, 2020
|
By:
|
/s/ Tony
(Bizuo) Liu
|
|
|
|
|
Tony
(Bizuo) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|